Lux Capital

Founded in 2000 by Peter Hébert, Robert Paull, and Josh Wolfe, Lux Capital operates from New York City and Menlo Park with a singular thesis: back scientists and engineers working at the fringes of what exists to build what hasn't existed yet.

The firm's tagline is "We turn sci-fi into sci-fact." That is not marketing copy. Lux wrote one of the first checks into Anduril Industries when Palantir cofounder Trae Stephens was still building the pitch deck. The firm has backed Hugging Face when open-source AI infrastructure was considered niche. It deployed into applied AI, robotics, and synthetic biology before those categories became crowded.

In January 2026, Lux closed its largest fund to date: $1.5 billion for Fund IX, pushing total assets under management to $7 billion. The round drew attention precisely because it came in a difficult deployment environment. Limited partners—foundations, endowments, family offices—wrote the check because Lux has a documented track record of finding outlier companies before they are obvious.

This guide covers Lux's actual investment thesis, its portfolio, check size range, what the partners actually look for, and how to approach the firm with a realistic strategy.

Lux Capital invests in emerging technologies across life sciences, defense, manufacturing, aerospace, and artificial intelligence. The firm's approach is to systematically mine academia and government labs for technological opportunities that have matured beyond a proof-of-concept but have not yet attracted mainstream venture attention.

The core thesis: long-term bets on contrarians and outsiders who challenge the status quo. Lux explicitly describes itself as looking for founders working decades into the future to create worlds most people cannot imagine. The firm prefers to own a position before the narrative forms.

Unlike software-focused VCs that emphasize growth metrics and product-market fit, Lux has the patience and domain expertise to evaluate deep science. The firm has partners with backgrounds in government and defense—including retired four-star General Tony Thomas as a venture partner, and former American diplomat Brett McGurk, who joined as a venture partner in 2025. This gives the firm credibility with founders building in classified or semi-classified sectors.

Lux has created more than 20 new companies from scratch. The firm does not only respond to inbound deals; it identifies gaps in the market and recruits founders to fill them. This makes the firm more of a co-founder than a passive investor in many cases.

The firm invests across the full spectrum of stages, from pre-seed (as low as $100K) to growth equity (up to $100M). The check size is determined by the opportunity, not a fixed allocation per stage. If a company is pre-revenue and pre-product but has a breakthrough in synthetic biology, Lux may write a $2M seed check. If a company is at Series B with $50M in ARR benchmarks, the check can be substantially larger.

Sector concentration includes AI and machine learning, climate technology, defense and dual-use technology, aerospace, robotics, biotechnology, advanced manufacturing, computational imaging, semiconductors, synthetic biology, and healthcare technology.

Lux Capital deployed over $450 million in Q2 2025 alone, describing it as one of the highest-quality cohorts of founders and opportunities in the firm's history. The firm maintains a consistent deployment pace regardless of market conditions, using the 2022-2024 downturn to find positions in companies that would have been too expensive in 2021.

In January 2026, the firm announced Fund IX at $1.5 billion—the largest in its more than twenty-year history. The fund will deploy across the same thesis: physical sciences, computational sciences, and life sciences. The firm specifically highlighted defense and national security as areas of increasing conviction, a view shaped by its portfolio exposure and geopolitical trends.

The firm has been particularly active in defense technology, having written early checks into Anduril when defense tech was broadly considered an orphan category in Silicon Valley. That position is now among the most valuable in the firm's history as Anduril raises at a reported $30.5 billion valuation. Lux has maintained its ownership and participated in follow-on rounds.

Lux has also been active in AI infrastructure, robotics, and climate tech. The firm backed Hugging Face early and has continued to support the AI platform through its rapid growth. In 2024 and 2025, the firm made meaningful investments into AI reasoning, autonomous systems, and space technology.

The firm's Q4 2025 letter explicitly addressed geopolitical trends as material to portfolio company performance. Given the firm's exposure to defense and dual-use technology, this is not surprising. Lux has described its investment process as including scenario planning around geopolitical shifts that could create tailwinds or headwinds for portfolio companies.

Lux Capital's portfolio reflects its thesis: pick the hardest, most ambitious problems and find the founders technical enough to actually solve them.

Anduril Industries is the crown jewel of the defense portfolio. Founded in 2017 by Palmer Luckey, the company builds autonomous drones, AI-powered defense systems, and hardware-software integrated platforms for national security. Lux wrote one of the first checks. As of 2026, Anduril is raising at a reported $30.5 billion valuation, making it one of the most valuable private defense companies in the world.

Applied Intuition provides simulation and validation infrastructure for autonomous vehicles and defense systems. The company is valued at approximately $15 billion. Founded by Qasaid CEO Peter Ludwig and CTO Jared Jacobs, the company addresses a critical bottleneck in the autonomous systems supply chain.

Hugging Face has become the dominant platform for open-source AI model development. Lux was an early backer when the company was still a small team focused on natural language processing. The company has since grown into a central infrastructure layer for the AI industry.

Saildrone builds wind-powered autonomous surface vehicles for ocean data collection and maritime domain awareness. The company has won significant U.S. government contracts and operates globally. It represents Lux's thesis around defense and climate intersection—dual-use technology with both commercial and national security applications.

Runway is a generative AI company focused on video generation and editing, used by media companies and enterprises for content creation. The company has grown substantially since Lux's early investment.

In the life sciences, portfolio companies include Eikon Therapeutics (computational imaging for drug discovery), eGenesis (gene editing for xenotransplantation), and Benchling (cloud-based R&D platform for biotech). Benchling achieved unicorn status, and eGenesis has advanced toward clinical-stage work in organ transplantation.

The firm has also backed Impulse Space (orbital transfer vehicles), Hadrian (advanced manufacturing for semiconductors), Terra Industries (agricultural technology), and Kela (defense intelligence). Varda Space Industries, which manufactures pharmaceuticals in orbit, is also in the portfolio.

On the frontier of AI reasoning, Lux has invested in Cognition AI, the company behind the Devin AI coding assistant. This positions the firm in the rapidly evolving AI agent category.

Lux evaluates investments on founder depth, technical differentiation, and timing against technology maturation curves.

Founder quality is non-negotiable. The firm looks for scientists and engineers who have spent years inside the problem they are solving. A founder who has published seminal papers in a field, worked at a national lab, or led a major program at a defense contractor will get serious consideration. Lux is not the right firm for a first-time founder with a generic SaaS pitch.

Technical moats matter more than growth metrics at the early stage. The firm wants to see defensible intellectual property, proprietary datasets, or exclusive access to research findings. If a competitor could replicate the core technology within eighteen months with adequate funding, Lux will pass.

The firm is explicitly comfortable with pre-product, pre-revenue, pre-company investments. Lux has created dozens of companies by identifying a technology gap and recruiting a founder to fill it. If a scientist has a breakthrough with no commercial infrastructure around it, Lux can be the first capital.

Market timing is a significant variable. Lux looks for technologies that have reached an inflection point where the science is proven enough to de-risk but the commercial application is not yet crowded. The firm is not interested in areas where the technology is still speculative or where the commercial pathway is unclear.

Dual-use technology is a recurring theme. Companies that serve both commercial and government customers—and where the government customer provides a stable anchor while commercial markets develop—are particularly attractive. Anduril and Saildrone are the clearest examples in the portfolio.

Lux evaluates competitive positioning carefully. The firm looks for companies with clear advantages that compound over time: proprietary data, network effects, exclusive partnerships, or regulatory advantages. A company that wins on price or features alone is not durable enough for Lux's portfolio.

The most effective path to Lux is a warm introduction from a portfolio founder, a scientist the firm respects, or a co-investor with whom Lux has an existing relationship. The firm sees thousands of inbound decks annually. A recommendation from a credible source in the technical community will get a meeting where a cold email will not.

For founders working in universities or national labs, Lux has a systematic sourcing operation that reviews published research, patent filings, and conference presentations. Building visibility in the academic community—by publishing, speaking at relevant conferences, or contributing to open-source projects—can draw the firm's attention without an explicit introduction.

Cold outreach is possible but must be highly targeted. The deck should demonstrate deep technical understanding of the problem. Generic SaaS pitch decks will be rejected immediately. The pitch should lead with the science, the founder's unique access to it, and the commercial timing. Do not lead with market size or growth projections; those are secondary to Lux's evaluation framework.

The firm has specific sector coverage, and each partner focuses on specific verticals. Research which partner covers your sector before reaching out. Sending a deck to the wrong partner will delay or kill the evaluation.

Meetings with Lux tend to be substantive and technical. The partners will probe the science, the technical constraints, and the founder's depth of understanding. Be prepared for rigorous technical questions, not standard VC questions about TAM and competition. The firm is evaluating whether you understand the problem better than anyone else in the room.

After an initial meeting, the decision timeline is typically two to four weeks for standard deals. The firm can move faster for competitive situations, and slower for complex deals in the life sciences that require deeper technical diligence.

Follow-up discipline matters. Lux will go quiet after a meeting even if they are interested. Send periodic updates on technical milestones—not just business metrics. The firm is tracking technical progress more closely than business metrics at the early stage.

Building a long-term relationship with Lux is valuable even if the current round does not close. The firm is a co-creator of companies, not just a capital provider. If you are working in a sector where Lux has conviction but the timing is not right, stay connected and the firm will likely re-engage as the technology matures.

While Lux invests in pre-revenue companies, they expect founders to have a rigorous handle on the financial mechanics of their business. For deep science companies, this includes a clear model for how costs scale with growth, the path to SaaS unit economics breakeven, and realistic assumptions about the capital required to reach clinical or commercial milestones.

For companies in the defense sector, understanding the different contracting mechanisms, compliance requirements, and government accounting is essential. Defense investors evaluate companies on their ability to navigate these complexities, not just on the technology.

Founders who lack this financial depth should work with a fractional CFO who has experience in the relevant sector. The extra credibility in a diligence process is real. Lux will probe the financial model carefully, and a founder who cannot defend their assumptions will lose credibility with the investment committee.

For life science companies, Lux expects detailed models around clinical trial costs, regulatory pathways, and the capital required to reach key inflection points. The firm has deep experience in biotech investing and will stress-test every assumption.

Financial projections should be grounded in evidence, not aspirational growth rates. The firm will challenge projections that do not reflect realistic timelines for technology development, regulatory approval, or customer acquisition in technical B2B markets.

Understanding the key performance indicators specific to your sector matters more than generic SaaS financial metrics. Be prepared to explain what metrics you track, why those metrics matter, and what the trends in those metrics tell you about the business.

Whether you are preparing for a Lux Capital pitch or engaging with other deep tech investors, having a credible financial model and a CFO who can defend every assumption sets you apart. The firms that write $10 million checks do not make those decisions based on decks alone—they make them based on diligence, and the founders who survive that diligence most cleanly are the ones who know their numbers better than anyone in the room.

Exploring other venture capital firms with a similar thesis? Our comprehensive collection of VC firm reviews covers deep tech, defense, and life science investors across all stages.

Each review provides detailed information about investment criteria, portfolio companies, and strategies for securing funding. Whether you are building in AI infrastructure, defense technology, or synthetic biology, you will find relevant insights in our firm guides.

Finding the right investor for your deep tech company is critical. The wrong VC will push for growth over scientific rigor. The right VC will support the timeline required to build something durable.